SPL Medical, based at the Novio Tech Campus in Nijmegen, is starting an international registration study for its contrast agent ferrotran. The study, which aims to demonstrate the diagnostic efficacy of the agent, is being conducted in ten hospitals in Germany, Switzerland and the Netherlands, including Radboudumc.
Mini-metastases in the picture
Ferrotran is a product of the Radboudumc spin-off SPL Medical. The contrast agent makes very small metastases in the lymph nodes highly visible on MRI scans. Even mini-metastases less than two millimeters in diameter can be detected with this approach. The drug consists of nano-iron particles, which make normal lymph nodes on an MRI scan appear black, while abnormal glands appear white. This makes it very easy to distinguish them from each other. Because ferrotran also makes the lymph vessels visible, the mini-metastases can be located with outstanding accuracy. This enables treatment – for example with targeted radiotherapy – at an early stage, resulting in fewer side effects and improving the chance of a cure. Other diagnostic techniques are limited in resolution to four to six millimeters and cannot detect such small metastases.
The first version of the product was developed in the USA in the late 1990s. Jelle Barentsz, professor of Functional Imaging at Radboudumc, discovered the value of this drug in patients with lymph node metastases. "He managed to obtain the rights for the drug for Radboudumc," says Harrie van Baars, Chief Business Officer at SPL Medical. "He then continued developing the product to make very small metastases visible."
According to Barentsz, clinical studies at Radboudumc have included hundreds of patients with various forms of cancer, such as cancer of the rectum, esophagus, pancreas, head-and-neck and prostate. "The results were so encouraging," he says, "that the product was privatized in 2015 with the spin-off SPL Medical."
Although a great deal of research data on ferrotran has been published in scientific journals, the product has not yet been authorized for the market. This requires a clinical registration study, which is now beginning. Van Baars: “This study is the prelude to the official authorization and market introduction of the product in Europe. We will study the use of ferrotran in 180 patients in ten hospitals in Germany, Switzerland and the Netherlands, including Radboudumc."
Although the agent has not yet been authorized for the market, it can sometimes be used for approved clinical studies, such as those taking place at Radboudumc. Some hospitals can also use the agent under strict conditions as part of a ‘compassionate use’ program for patients with life-threatening, long-lasting or seriously debilitating illnesses. Van Baars: “In that context, the first patient with metastatic prostate cancer in Switzerland has recently received ferrotran. With the clinical trial and the compassionate use program, our goal of making ferrotran widely available for cancer patients has come much closer to realization.”
Related news items
Vulnerable Nijmegen citizens less likely to visit GP physically due to corona23 February 2021
The COVID-19 pandemic in 2020 in Nijmegen and the surrounding area led to a substantial decrease in GP consultations for patients with chronic physical health problems.read more
New Physical, Mental, and Cognitive Problems 1-year Post-ICU18 February 2021
Half of the Intensive Care Unit (ICU) survivors suffer from new physical, mental and/or cognitive problems one year after ICU admission. This is evident from the large-scale MONITOR-IC study led by the Radboudumc.read more
Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection17 February 2021
In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2.read more
Radboudumc and Quirem Medical sign cooperation agreement17 February 2021
Radboudumc and Quirem Medical signed an agreement for joint research. The agreement includes several existing and future projects based on small radioactive spheres. Enhanced cooperation should improve the treatment of cancer patients and stimulate research into new applications.read more
Dutch Kidney Foundation Innovation Grant for Tom Nijenhuis and Jeroen de Baaij17 February 2021
This innovation grant was awarded for their project “A sweet deal: repurposing SGLT2i for renal hypomagnesemia”.read more